In this video, Motley Fool health care bureau chief Brenton Flynn previews the Fool's premium report on Abbott Labs by outlining some risks facing the company. First, all of its business segments operate in highly competitive environments. Second, Abbott's international businesses are vulnerable to currency fluctuations and economic downturns, such as we see now in Europe. These downturns reduce consumer demand for Abbott's nutritional products, for example. Lastly, many foreign countries have a single-payor system for health care, and these might force Abbott to take suboptimal payments for its products.
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
What Are the Risks for Abbott Labs Investors?
NYSE: ABT
Abbott Laboratories

Holding a position in Abbott Labs? You need to know the risks.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles





Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.